Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 January 2021 | Story André Damons | Photo Supplied
Vincent Clarke
Dr Ralph Clark

The Afromontane Research Unit (ARU), the flagship research group of the University of the Free State (UFS) Qwaqwa Campus, has recently been granted R8,4 million to establish a Risk and Vulnerability Science Centre programme.

The Risk and Vulnerability Science Centre (RVSC) programme was established by the Department of Science and Innovation (DSI) as part of the Global Change Research Plan for South Africa and is funded by the DSI through the National Research Foundation (NRF). The RVSC will focus on the need to generate and disseminate knowledge about risk and vulnerability on global change challenges faced by local policy makers/ governance structures and communities in South Africa.

Invited to participate  

Dr Ralph Clark, Director of the ARU, says the UFS, together with the University of Zululand and the Sol Plaatje University, has been invited to participate in Phase 2 of the RVSC programme. Dr Clark was approached by the DSI (on referral from the South African Environmental Observation Network – SAEON) in February 2020 regarding the potential for establishing a RVSC at the UFS Qwaqwa campus.

Subsequent interactions were held between the UFS and DSI, and in March 2020, the UFS formally accepted the DSI invitation. It has since been agreed that the RVSC: UFS will be hosted as a RVSC under the ARU umbrella, with dedicated personnel embedded at the UFS in this regard (internal processes and reporting) but reporting directly to the NRF regarding the RVSC.

Interest and support welcomed

Dr Clark welcomed this interest and support from the DSI-NRF, saying that the funds will further assist the UFS in growing its excellent and growing research portfolio and building more research capacity on this traditionally undergraduate-focused campus. “The RVSC will contribute to much-needed solutions in an area marked by major sustainability challenges and will assist in moving Phuthaditjhaba away from its negative apartheid history towards becoming a sustainable African mountain city,” says Dr Clark.

News Archive

Collaboration between UFS and Mayo Clinic to revolutionise cancer treatment
2014-06-27



Attending the lecture were, from the left: Dr Chantel Swart, Prof Lodewyk Kock, Prof Debabrata Mukhopadhyay, Prof James du Preez; back: Prof Pieter van Wyk.
Dr Swart, Profs Kock and Du Preez are from the Department of Microbial, Biochemical and Food Biotechnology. Prof Mukhopadhyay is from the Mayo Clinic (US) and Prof Van Wyk is from the Centre for Microscopy at the UFS.
Photo: Supplied
The UFS made a discovery that may have enormous implications for the treatment of diseases in humans.

Since the discovery, the UFS joined forces with the Mayo Clinic in Rochester, US, in the fight against cancer.

In this collective effort, UFS researchers would be able to assist the Mayo team to:
• see how treatment in cancer patients is progressing,
• target treatments more effectively,
• reduce dosages in order to make treatment gentler on the patient,
• track the effectiveness of the chemotherapy drugs used, and
• gain an accurate view of how the cancer is being eliminated.

Prof Lodewyk Kock, Outstanding Professor at the Department of Microbial, Biochemical and Food Biotechnology, and his team incidentally created a technique to use argon gas particles for the first time on biological material to slice open cells to look inside.

The team that supported Prof Kock includes Dr Chantel Swart, Khumisho Dithebe (PhD student), Prof Hendrik Swart (Department of Physics) and Prof Pieter van Wyk (Centre for Microscopy).

Prof Debabrata Mukhopadhyay from the Mayo Clinic in Rochester, US, got to hear about this breakthrough at the UFS and a collaboration between the two institutions was established.

During a visit to the Bloemfontein Campus, Prof Mukhopadhyay explained novel techniques that make use of gold nanoparticles. These particles attach to chemotherapeutic drugs to selectively target cancer cells – dramatically decreasing the side effects to normal human cells.

For these new drugs (coupled to gold nanoparticles) to be accepted into clinical practice, visual and chemical proof is needed, though. This is where the technique developed by the UFS will play a vital role.

With the technique to look inside cells, the composition, location and metabolism of these drugs can be determined. This will aid in a proof of concept for the application of the nano-drugs. Furthermore, it will enable approval for use of these drugs in clinical trials and eventually could revolutionise cancer treatment as a whole.

For video lectures on the technique used, as well as its findings, follow these links:

1. http://vimeo.com/63643628 (Comic version for school kids)

2. http://vimeo.com/61521401 (Detailed version for fellow scientists)

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept